Immunotherapy study gives lung-cancer patients hope

To learn that you have lung cancer and that it has migrated elsewhere in your body is to be told some of the worst news a doctor can deliver. The prognosis is poor, and treatments aimed at preserving as much life as possible can be grueling, the side effects whittling away at the quality of the time you have. But that’s beginning to change for some lung-cancer patients as therapies that are designed to work with a person’s immune system stall and shrink tumors.